Navigation Links
Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
Date:3/11/2010

THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the methods of expressing, secreting, and purifying the NELL-1 sequence of the UCB-1 recombinant protein wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell. This patent continues the creation of a patent portfolio for musculoskeletal applications of manufacturing and use in bone regeneration and repair as well as cartilage regeneration and repair.  

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX® demineralized bone matrix, to promote bone growth in spinal fusion. DBX® is a product of the Musculoskeletal Transplant Foundation, a Bone Biologics partner.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.    

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "This patent issuance is a significant milestone in our efforts to realize the full potential of the UCB-1 protein as a platform technology. We very much appreciate the continued support of MTF on this project."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clive Dix Appointed as Chairman of Crescendo Biologics
2. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
3. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
4. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
5. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
6. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
7. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):